Ligand deconstruction: Why some fragment binding positions are conserved and others are not

Significance Fragment-based drug discovery (FBDD), in which initial screening is done with low-molecular-weight compounds called fragments, relies on the premise that the fragment binding mode will be conserved on subsequent expansion to a larger ligand. We describe a remarkably simple condition for fragment binding conservation that can be tested computationally. The condition can be used for detecting whether a protein is suitable for FBDD, for predicting the size of fragments required for screening, and for determining if a fragment hit can be extended into a higher affinity ligand. The findings also reveal general properties of binding sites, highlighting the role that critical interactions between anchor sites and anchor fragments play in protein–ligand interactions in general. Fragment-based drug discovery (FBDD) relies on the premise that the fragment binding mode will be conserved on subsequent expansion to a larger ligand. However, no general condition has been established to explain when fragment binding modes will be conserved. We show that a remarkably simple condition can be developed in terms of how fragments coincide with binding energy hot spots—regions of the protein where interactions with a ligand contribute substantial binding free energy—the locations of which can easily be determined computationally. Because a substantial fraction of the free energy of ligand binding comes from interacting with the residues in the energetically most important hot spot, a ligand moiety that sufficiently overlaps with this region will retain its location even when other parts of the ligand are removed. This hypothesis is supported by eight case studies. The condition helps identify whether a protein is suitable for FBDD, predicts the size of fragments required for screening, and determines whether a fragment hit can be extended into a higher affinity ligand. Our results show that ligand binding sites can usefully be thought of in terms of an anchor site, which is the top-ranked hot spot and dominates the free energy of binding, surrounded by a number of weaker satellite sites that confer improved affinity and selectivity for a particular ligand and that it is the intrinsic binding potential of the protein surface that determines whether it can serve as a robust binding site for a suitably optimized ligand.

[1]  W. Delano Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[2]  Andreas Thomann,et al.  Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. , 2012, Chemistry & biology.

[3]  A. Abbas,et al.  Interleukin‐2 in the development and control of inflammatory disease , 2008, Immunological reviews.

[4]  Brian K Shoichet,et al.  Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. , 2002, Journal of molecular biology.

[5]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[6]  P. Hajduk Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[7]  Ian M. Eggleston,et al.  Structure-Based Dissection of the Natural Product Cyclopentapeptide Chitinase Inhibitor Argifin , 2008, Chemistry & biology.

[8]  Daniel S. Hitchcock,et al.  Substrate Deconstruction and the Nonadditivity of Enzyme Recognition , 2014, Journal of the American Chemical Society.

[9]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[10]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[11]  Manuele Bicego,et al.  In Silico Deconstruction of ATP-Competitive Inhibitors of Glycogen Synthase Kinase-3β , 2012, J. Chem. Inf. Model..

[12]  Julien Michel,et al.  Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.

[13]  Robert P. Smart,et al.  Structure-based efforts to optimize a non-β-lactam inhibitor of AmpC β-lactamase. , 2014, Bioorganic & medicinal chemistry.

[14]  Peter Brandt,et al.  Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. , 2011, Journal of medicinal chemistry.

[15]  M. Randal,et al.  Potent small-molecule binding to a dynamic hot spot on IL-2. , 2003, Journal of the American Chemical Society.

[16]  Dima Kozakov,et al.  Relationship between Hot Spot Residues and Ligand Binding Hot Spots in Protein-Protein Interfaces , 2012, J. Chem. Inf. Model..

[17]  G. Scapin,et al.  Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[18]  T. Blundell,et al.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.

[19]  Mike Cherry,et al.  Introduction to Fragment‐Based Drug Discovery , 2008 .

[20]  D. Bernard,et al.  Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.

[21]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[23]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[24]  Ning Sun,et al.  Validation of the AmpC β-Lactamase Binding Site and Identification of Inhibitors with Novel Scaffolds , 2012, J. Chem. Inf. Model..

[25]  Dima Kozakov,et al.  Hot Spot Analysis for Driving the Development of Hits into Leads in Fragment-Based Drug Discovery , 2012, J. Chem. Inf. Model..

[26]  Sandor Vajda,et al.  Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.

[27]  Elizabeth A. Villar,et al.  Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interface. , 2013, Journal of the American Chemical Society.

[28]  S. Barelier,et al.  Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.

[29]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[30]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[31]  Dima Kozakov,et al.  Analysis of binding site hot spots on the surface of Ras GTPase. , 2011, Journal of molecular biology.

[32]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[33]  Maria Paola Costi,et al.  Targeting Class A and C Serine β-Lactamases with a Broad-Spectrum Boronic Acid Derivative , 2014, Journal of medicinal chemistry.

[34]  Dima Kozakov,et al.  Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase , 2009, J. Comput. Aided Mol. Des..

[35]  Denise G. Teotico,et al.  Docking for fragment inhibitors of AmpC β-lactamase , 2009, Proceedings of the National Academy of Sciences.

[36]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[37]  E. Mandine,et al.  Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. , 2003, Journal of medicinal chemistry.

[38]  L. Mario Amzel,et al.  Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.

[39]  Roderick E Hubbard,et al.  Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.

[40]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[41]  D. Ringe,et al.  Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.

[42]  Masaya Orita,et al.  Lead generation and examples opinion regarding how to follow up hits. , 2011, Methods in enzymology.

[43]  Gianni Chessari,et al.  Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.

[44]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[45]  Binh Vu,et al.  Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.

[46]  C. Geraldes,et al.  Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions? , 2013, ACS medicinal chemistry letters.

[47]  G. Scapin,et al.  (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2006, Journal of medicinal chemistry.

[48]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[49]  Karen N. Allen,et al.  An Experimental Approach to Mapping the Binding Surfaces of Crystalline Proteins , 1996 .

[50]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[51]  Daniel A Erlanson,et al.  Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.

[52]  Dima Kozakov,et al.  Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. , 2009, Biophysical journal.

[53]  F. J. Luque,et al.  Binding site detection and druggability index from first principles. , 2009, Journal of medicinal chemistry.

[54]  Dima Kozakov,et al.  The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins , 2015, Nature Protocols.

[55]  Tom L. Blundell,et al.  Biophysical and computational fragment-based approaches to targeting protein–protein interactions: applications in structure-guided drug discovery , 2012, Quarterly Reviews of Biophysics.

[56]  Dima Kozakov,et al.  Robust Identification of Binding Hot Spots Using Continuum Electrostatics: Application to Hen Egg-White Lysozyme , 2011, Journal of the American Chemical Society.

[57]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[58]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[59]  Laurie E. Grove,et al.  Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.

[60]  Chris Abell,et al.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.

[61]  Daniel A. Erlanson,et al.  Fragment‐Based Drug Discovery. , 2004 .

[62]  Pedro Soares,et al.  Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities , 2014, Journal of medicinal chemistry.